

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: J. Timothy Greenamyre, et al. :

APPLICATION NO.: 09/148,973

: Examiner: Hsu, G.

FILING DATE: September 4, 1998

: Group Art Unit: 1627

TITLE: METHODS OF ADMINISTERING AN
AMPA RECEPTOR ANTAGONIST TO
TREAT DYSKINESIAS ASSOCIATED
WITH DOPAMINE AGONIST THERAPY

BY MESSENGER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is a supplement to the Information Disclosure Statement filed in connection with the above-identified application on March 20, 1999.

Applicants herein make available to the United States Patent and Trademark Office a copy of a form conforming to PTO-FB-A820 which lists the following references cited in the partial European Search Report issued March 21, 2001 in connection with the counterpart European patent application, Application No. 98306661.4. A copy of the March 21, 2001 partial Search Report and of each reference is also enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 CFR 1.104(a):

1. Loschmann P., et al. "Synergism of the AMPA-Antagonist NBQX and the NMDA-Antagonist CPP with L-Dopa in Models of Parkinson's Disease, J. Neural Transm [P-D Sect] (1991) 3: 203-213;
2. WO 93/08173 A, (Schering AG), April 29, 1993;
3. WO 92/13535 A, (Dwivedi Chandradhar; Omodt Gary W.), August 20, 1992;

RECEIVED

APR 12 2001

TECH CENTER 1600/2900

RECEIVED
TECH CENTER 1600/2900
01 APR 11 PM 1:06

4. U.S. 4,183,931 A, Wolfe, et al., January 15, 1980;
5. Koe, B. K., et al., "Enhancement of Benzodiazepine Binding by Methaqualone and Related Quinazolinones" Drug Development Research 7:255-268 (1986), vol. 7, no. 3, pp. 255-268; and
6. WO 97/43276 A (Pfizer), November 20, 1997.


It is requested that the references listed above and on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (MPEP 1302.12).

Although no fee is believed necessary for filing this Supplemental Information Disclosure Statement, if any fee is deemed necessary in connection with filing this Supplemental Information Disclosure Statement, authorization is hereby given to charge such fee to Deposit Account No. 16-1445.

Respectfully submitted,

Date:

April 10, 2001



Kristina L. Konstas

Attorney for Applicant(s)

Reg. No. 37,864

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-6380